NEULANDLAB23,800.00

Neuland Laboratories Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersDIVISLABLAURUSLABSNHNATCOPHARMLALPATHLABSAILIFECOHANCEASTERDMMcap ₹30,703 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,558.61,476.82,023.02,371.8
Other Income12.520.530.230.8
Total Income1,571.11,497.32,053.22,402.6
Expenses
+ Cost of Materials Consumed632.4574.8819.8887.1
+ Changes in Inventories-55.112.8-64.3-24.1
+ Employee Benefit Expense257.1272.0341.1374.1
+ Finance Costs14.08.323.926.3
+ Depreciation & Amortisation59.765.591.798.1
+ Other Expenses261.6293.9351.8371.8
Total Expenses1,169.71,227.41,564.21,733.4
EBITDA462.6323.3574.5762.9
EBIT402.9257.7482.8664.8
Profit
PBT before Exceptional Items401.4269.9489.0669.3
+ Exceptional Items0.076.40.00.0
Pretax Income401.4346.3489.0669.3
+ Current Tax99.773.8129.0175.5
+ Deferred Tax1.712.5-4.0-4.0
Tax Expense101.486.2125.0171.5
Net Income300.1260.1364.0497.8
+ Net Income — Continuing Ops300.1260.1364.0497.8
+ Other Comprehensive Income1.4-0.01.10.9
Total Comprehensive Income301.4260.1365.1498.6
Net Income to Common0.00.0364.0400.9
Per Share
Basic EPS233.89202.74283.71387.97
Diluted EPS233.89202.74283.71387.97
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.01.10.9
+ Items NOT to be Reclassified to P&L1.4-0.30.5
+ Tax on Items NOT to be Reclassified-0.10.1
+ Items to be Reclassified to P&L0.20.7
+ Tax on Items to be Reclassified0.00.00.1
+ Tax on Items to be Reclassified — alt tag0.0
Comprehensive Income — Owners of Parent0.00.0365.1401.9
Per Share — as-filed variants
Basic EPS — Continuing Operations233.89202.74283.71387.97
Diluted EPS — Continuing Operations233.89202.74283.71387.97
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit981.3889.21,267.51,508.8
Gross Margin %62.9660.2162.6563.62
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)401.4269.9489.0669.3
− Exceptional Items (reconciliation)0.076.40.00.0
Net Income Adj (tax-effected)300.1202.7364.0497.8
EPS Adj233.89158.01283.71387.97
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital12.912.912.912.9
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.